CGON Price Prediction Next Week
Analysis and Insights
Technical Analysis:
CGON's stock has shown signs of potential reversal after entering oversold territory. The Relative Strength Index (RSI) of 28.3 indicates exhaustion of selling pressure, suggesting a possible buying opportunity. The stock is currently trading at $25.23, near the low end of its 52-week range, which could signal undervaluation.
Fibonacci Levels:
The Fibonacci levels suggest key support and resistance points. The pivot point is at $27.13, with resistance levels at $28.47 and $29.30. A break above these levels could indicate a bullish trend.
Analyst Sentiment:
Analysts maintain a Strong Buy rating on CGON, with an average price target of $68.80. This indicates confidence in the stock's long-term growth potential.
Conclusion:
Based on the oversold condition, bullish technical indicators, and positive analyst sentiment, CGON is expected to rise. The predicted price for the next trading week is $29.58, and the recommendation is to buy.
CGON Similar Chart Price Prediction
The price of CGON is predicted to go up 2.42%, based on the high correlation periods with CPHC. The similarity of these two price pattern on the periods is 91.52%.
CGON
CPHC
Up: 2.42%Similarity: 91.52%
CGON Revenue Forecast
CGON EPS Forecast
CGON FAQs
What is CGON revenue forecast for next quarter？
CGON Analyst's Forecast
Jeffrey Hung
Morgan Stanley
Buy
2025-03-07
Price Target
$55
Upside
+105.84%
Morgan Stanley assumed coverage of CG Oncology with an Overweight rating and $55 price target. Morgan Stanley sees a competitive profile for cretostimogene in bladder cancer, with indication expansion potential beyond high-risk Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. In addition to strong data, the firm thinks the familiarity of the same route of administration as standard-of-care BCG therapy should help encourage urologists to prescribe cretostimogene once approved.
Tyler Van Buren
TD Cowen
Strong Buy
2025-01-07
Price Target
n/a
Downside
0%
